The SRC (sarcoma) gene is mapped to human chromosome 20q11.23. It is found to be highly expressed in the brain and platelets. It belongs to the Src family of tyrosine kinases. These kinases contain a unique myristylated N-terminal domain, followed by a SH3 domain, the SH2 domain, the tyrosine kinase domain, and a short C-terminal tail.
Synonyms: Anti-ASV; Anti-SRC1; Anti-c-src
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: The SRC (sarcoma) gene encodes a proto-oncogene that has been found to be overexpressed in several human cancers. By being a part of several signaling pathways, it is found to regulate proliferation, survival, metastasis, and angiogenesis. This nonreceptor tyrosine kinase is involved in the transduction of signals from growth factors, such as EGFR (epidermal growth factor receptor). It is found to participate in EGF-induced mitogenesis and transformation.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC